comparemela.com

Latest Breaking News On - Heritage provider network - Page 10 : comparemela.com

Filipino-led biotech firm raises P10B for cancer research

Filipino-led biotech firm raises P10B for cancer research
sunstar.com.ph - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sunstar.com.ph Daily Mail and Mail on Sunday newspapers.

Filipino biotech firm InterVenn raises P10B for immuno-oncology test

Filipino biotech firm InterVenn raises P10B for immuno-oncology test
bworldonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bworldonline.com Daily Mail and Mail on Sunday newspapers.

Follow the Money: RNA Therapeutics, AI-Driven Therapy Design

Follow the Money: RNA Therapeutics, AI-Driven Therapy Design
bio-itworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bio-itworld.com Daily Mail and Mail on Sunday newspapers.

The Funded: San Francisco startups raised $263 million in the middle of this week, despite all the exodus talk

The Funded: San Francisco startups raised $263 million in the middle of this week, despite all the exodus talk
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.

InterVenn Biosciences Raises $201M in Series C Funding

InterVenn Biosciences, a South San Francisco, Calif.-based company that utilizes a proprietary glycoproteomics biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine, completed a $201m Series C financing. The round was led by new investors SoftBank Group, Heritage Provider Network, Irving Investors, Highside Capital Management, and backed by existing investors Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures. The company intends to use the funds to accelerate development and commercialization of Dawn™, a liquid biopsy assay for immune checkpoint inhibitor response prediction, and to expand the network of partners on its AI-driven glycoproteomics platform to accelerate development and commercialization of new clinical solutions, and broaden insights into new biomarkers and therapies.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.